- Cosentyx also added to public drug plans in British Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Prince Edward Island and Newfoundland and Labrador and the NIHB Benefits List
- Psoriatic arthritis and ankylosing spondylitis are long-term, debilitating conditions which affect the joints and spine1,2,3
DORVAL, QC, June 6, 2018 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Ontario will now reimburse Cosentyx® (secukinumab) under the province's public drug program for eligible adults with active psoriatic arthritis (PsA) and eligible adults with ankylosing spondylitis (AS).
Both PsA and AS are inflammatory diseases. PsA affects the joints and is often accompanied by psoriasis and AS primarily affects the spine, which causes inflammation of the spinal joints4. AS is a chronic, progressive, painful form of inflammatory arthritis5.
"Ankylosing spondylitis and psoriatic arthritis affect people of all ages. They are painful and often progressively debilitating conditions that can lead to irreversible joint damage and can have a major impact on quality of life," said Dr. Algis Jovaisas, Rheumatologist and Medical Director of Capital North Therapeutics & Research in Ottawa. "The public reimbursement of Cosentyx in Ontario and many other parts of Canada for these two conditions represents an important milestone for patients and their treating practitioners, enabling us to treat patients earlier in the course of their disease with the goal of preventing damage and long-term disability."
In adults with active PsA, Cosentyx can be used alone or with methotrexate4. Cosentyx can also be prescribed for adults with active AS who do not respond adequately to previous disease-modifying anti-rheumatic drug (DMARD) therapy4.
In addition to being funded in Ontario, Cosentyx is also available through the public drug plans in British Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Prince Edward Island, and Newfoundland and Labrador for patients living with PsA and AS who meet specific criteria and for those covered under the Non-Insured Health Benefit's (NIHB) Program.
"We are pleased with this announcement by the Ontario government and decision makers across the country, marking a positive step forward in the management of PsA and AS. The team at Novartis is committed to supporting all patients living with these inflammatory diseases to live better and healthier lives," said Janice Murray, President, Novartis Pharmaceuticals Canada Inc. "As always we will continue to work collaboratively with the remaining provinces and territories to ensure patients from all corners of Canada with PsA and AS and their health care providers have public access to Cosentyx as soon as possible."
About Cosentyx (secukinumab) and interleukin-17A (IL-17A)
Secukinumab is a human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)4. IL-17A is one of the many proteins in the body called cytokines that help protect the body against infections4. It has been identified as playing a key role in a number of immune-mediated diseases including psoriasis6. Cosentyx is approved for the treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Cosentyx can be used alone or in combination with methotrexate. Cosentyx is also approved for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy and for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy4.
About Novartis Pharmaceuticals Canada
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2017, the company invested $51 million in research and development in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 750 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. For further information, please consult www.novartis.ca.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Cosentyx® is a registered trademark
SOURCE Novartis Pharmaceuticals Canada Inc.
For further information: Novartis Media Relations, Julie Schneiderman, Novartis Pharmaceuticals Communications, +1 514 633-7873, E-mail: email@example.com; Spectrum Advisors, +1 514 234 4095, firstname.lastname@example.org